Penumbra Q1 2022 Earnings Report

Total revenue increased to $203.9 million for the first quarter of 2022 compared to $169.2 million for the first quarter of 2021, an increase of 20.5%.

Revenue from sales of vascular products grew to $122.8 million for the first quarter of 2022, an increase of 37.7%.

Revenue from sales of neuro products grew to $81.1 million for the first quarter of 2022, an increase of 1.3%.

Gross profit was $127.4 million, or 62.5% of total revenue for the first quarter of 2022.